Market Place
Sourcing Support
OSE Reports Positive Progress For Tedopi® Cancer Vaccine
11 Dec 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Strengthens Leadership And Executive Team
02 Dec 2024 //
GLOBENEWSWIRE
OSE Immuno Announces Positive Lusvertikimab UC Phase 2 Data
04 Nov 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Presents New “Cis-Demasking” Technology
17 Oct 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Announces H1 2024 Results
26 Sep 2024 //
GLOBENEWSWIRE
OSE Immuno Launches Artemia Phase 3 Study for Cancer Vaccine
10 Sep 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports Positive Phase 2 Lusvertikimab Results
24 Jul 2024 //
GLOBENEWSWIRE
OSE Reports Symptom Improvements For Ulcerative Colitis Drug
24 Jul 2024 //
FIERCE BIOTECH
Boehringer and OSE to advance cancer immunotherapy to clinics
04 Jul 2024 //
PHARMACEUTICAL TECHNOLOGY
OSE Announces Publication of Preclinical Results with Lusvertikimab in Leukemia
01 Jul 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Enters Agreement With MSK For CAR T-Cell Therapies
25 Jun 2024 //
PHARMABIZ
OSE announces CAR T-cell therapy commercial and revenue sharing agreement.
24 Jun 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Presents MRNA Platform Data At FOCIS Annual Meeting
20 Jun 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports On 2024 Meeting And Board Evolution
19 Jun 2024 //
GLOBENEWSWIRE
OSE, Nantes: Positive Renal Transplant Immunotherapy Data
05 Jun 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Provides Business and Corporate Update
30 May 2024 //
GLOBENEWSWIRE
Boehringer And OSE Expand Collaboration For Cancer And Cardio-Renal Therapies
22 May 2024 //
PRESS RELEASE
OSE, Boehringer Expand Collaboration For Cancer, Cardio-Renal Treatments
22 May 2024 //
GLOBENEWSWIRE
Boehringer pays OSE $42M to grab new asset, expand into cardio
22 May 2024 //
FIERCE BIOTECH
OSE Immunotherapeutics Receives Public Funding for Tedopi® Trial
10 Apr 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Highlights Advancements and Provides 2024 Outlook
19 Jan 2024 //
BUSINESSWIRE
OSE Immunotherapeutics Announces First Clinical Results for BI 770371
23 Oct 2023 //
BUSINESSWIRE
OSE Immuno Presents First Positive Clinical Results With its anti-PD1 OSE-279
16 Oct 2023 //
BUSINESSWIRE
OSE: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients
11 Sep 2023 //
BUSINESSWIRE
OSE Immuno Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist:
06 Jul 2023 //
BUSINESSWIRE
OSE Immuno Announces US Patent Granted for the Use of Tedopi in Cancer Patients
04 Jul 2023 //
BUSINESSWIRE
OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance
20 Jun 2023 //
BUSINESSWIRE
OSE Immunotherapeutics Presents Update on BiCKI®IL-7
15 Jun 2023 //
BUSINESSWIRE
OSE Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting
06 Jun 2023 //
BUSINESSWIRE
OSE Immunotherapeutics Reports Full Year 2022 Financial Results
27 Apr 2023 //
BUSINESSWIRE
OSE Immunotherapeutics Provides Regulatory Update on Tedopi
15 Feb 2023 //
BUSINESSWIRE
OSE Immunotherapeutics Announces First Patient Dosed with Anti-PD1 OSE-279
23 Dec 2022 //
PHARMAFILE
Gilead Sciences to acquire OSE portfolio company for approximately $405m
16 Aug 2022 //
PHARMACEUTICAL MANUFACTURER
OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer
13 Jul 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports on 2022 Combined General Shareholder`s Meeting
23 Jun 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics Announces Collaboration with Microsoft
16 Jun 2022 //
BIOSPACE
OSE Immunotherapeutics Appoints its International Scientific Advisory Board
09 Jun 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics: 4 Poster Presentations of Neoepitope Combination Tedopi
23 May 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics Begins Dosing in PI Study of VEL-101/FR104
18 May 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics To Present at two summits In London and Boston
11 May 2022 //
GLOBENEWSWIRE
BI and OSE Immunotherapeutics Begins Dosing in PI Expansion Trial of BI 765063
03 May 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1
02 May 2022 //
GLOBENEWSWIRE
OSE Immuno to Present Preclinical Data on BiCKI-IL-7 Cancer Immunotherapy
04 Apr 2022 //
GLOBENEWSWIRE
OSE ImmunoTx Provides Positive Long Term Memory Responses with CoVepiT
16 Mar 2022 //
GLOBENEWSWIRE
OSE Immuno to present biomarker analyses from phase 1 trial of BI 765063
10 Mar 2022 //
PHARMABIZ
OSE Immunotherapeutics Appoints Alexandre Lebeaut in Board of Directors
18 Feb 2022 //
GLOBENEWSWIRE
Veloxis Pharmaceuticals Obtains FDA FTD for CD28 Antagonist VEL-101/FR104
17 Feb 2022 //
GLOBENEWSWIRE
Transfer of OSE Immunotherapeutics’ Shares from January 31, 2022
01 Feb 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics Accepts US IND Obtained by Veloxis for VEL-101/FR104
31 Jan 2022 //
GLOBENEWSWIRE
OSE Immuno Receives First Notice of Allowance of Patent for Use of Tedopi
25 Jan 2022 //
GLOBENEWSWIRE
OSE Immunotherapeutics Appoints Dominique Costantini as Interim CEO
17 Jan 2022 //
GLOBENEWSWIRE
OSE to Present New Preclinical Data at Upcoming Bispecific Antibody
19 Oct 2021 //
GLOBENEWSWIRE
OSE Immunotherapeutics to Present New Clinical and Preclinical Data
13 Oct 2021 //
GLOBENEWSWIRE
OSE Immunothera Receives New European Patent Notice of Allowance for Tedopi®
11 Oct 2021 //
GLOBENEWSWIRE
OSE Immunotherapeutics Presented Positive Final Results of Tedopi Ph3 Trial
20 Sep 2021 //
GLOBENEWSWIRE
Boehringer Ingelheim, OSE Immunotherapeutics Present Phase 1 Data with BI 765063
16 Sep 2021 //
GLOBENEWSWIRE
OSE Immunotherapeutics gets US patent for Tedopi to treat NSCLC
08 Sep 2021 //
PHARMABIZ
OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®
07 Sep 2021 //
GLOBENEWSWIRE
